Cerebrovascular and Metabolic Alterations in a Mouse Model of Familial Alzheimer’s Disease Carrying the Notch3 C456R Mutation

Abstract Background Vascular pathology associated with small vessel disease (SVD), such as microinfarcts and microbleeds, are common in elderly populations and significant contributors to cognitive impairment and dementia. Autosomal dominant cerebral arteriopathy with subcortical infarctions and leukoencephalopathy (CADASIL), caused by mutations in the Notch3 gene, is the most prominent inheritable SVD, with a common etiology of subcortical strokes and dementia. This study aimed to investigate additive or synergistic effects of CADASIL‐related vascular alterations and familial Alzheimer’s disease (FAD)‐related amyloid pathology on cerebral metabolism of glucose and disease progression in a novel FAD‐CADASIL mouse model. Methods We bred 5xFAD mice to CADASIL mice carrying the Notch3 C456R mutation to create the novel FAD‐CADASIL mouse model. To investigate progressive alterations in cerebral glucose metabolism, 18 F‐FDG was delivered to awake mice via a tail vein injection, with an average dose of 18.5 MBq. The mice were fasted for a minimum of 2 hours before 18 F‐FDG administration. PET and CT acquisitions were completed after a 30‐minute 18 F‐FDG circulation period using a Bruker Si78 instrument. Static datasets were analyzed for standard uptake values relative to the brainstem (SUV r ) and corrected for glucose levels (SUV glc ). Statistical tests included unpaired t‐tests and 1‐ & 2‐way ANOVA using GraphPad Prism 9. Results Whole brain SUV r values were decreased across age groups in 5xFAD, Notch3 C456R , and 5xFAD/Notch3 C456R mice compared to age‐matched WT controls. Blood glucose levels collected before ligand injection indicated an age‐dependent decrease in glucose levels across all genotypes. 5xFAD/Notch3 C456R mice showed distinct reductions in whole brain SUV glc values compared to aged‐matched 5xFAD and Notch3 C456R mice. ROI analysis of 3‐month‐old 5xFAD/Notch3 C456R shows significantly decreased SUV glc levels in several cortical regions such as the striatum, cortex, hippocampus, hypothalamus, and thalamus when individually compared to WT, 5xFAD, and Notch3 C456R mice (Figure 1). Conclusion We observed a significant synergistic effect of CADASIL on accelerating increased amyloid accumulation and reducing cerebral glucose metabolism in the novel FAD‐CADASIL mouse model. These results provide further key evidence of an association between cortical vascular pathology and Alzheimer’s Disease progression. This research was funded by NIH/NINDS grant RF1NS117486.